retatrutide phase 2 trial dosing schedule as a Novel Treatment for Obesity and Type Diabetes Retatrutide dose: the complete guide

Begin at a lower escalation dose and work up gradually to allow your body to adjust to the third receptor target

This structural design represents a significant advance in peptide engineering and explains why retatrutide can act as a potent agonist at three different receptors while maintaining a favorable pharmacokinetic profile

Final Verdict Gentle Patches sells itself as GLP-1 support, but it isnt Ozempic, Wegovy, or any prescription therapy

A 48-week Phase 2 trial reported in The Lancet in 2025 showed mean weight reduction ranging from approximately 9% at the lowest dose to 20% at the highest dose, compared with 0.4% on placebo